Novartis data set up marketing battle over breast cancer drugs; Bernie's accidentally great drug pricing idea

Novartis said its CDK 4/6 inhibitor had succeeded in a Phase 3 trial — putting it in competition with drugs from Pfizer and Eli Lilly.

March 28, 2023 Check out STAT+

Sponsored By

Damian Dovarganes/AP STAT+ | Novartis data set up multibillion-dollar battle over breast cancer drugs The success of the trial of Kisqali, a CDK 4/6 inhibitor, could set up one of the biggest marketing battles in cancer. By Matthew Herper STAT+ | Bernie Sanders' accidentally great drug pricing idea What, Bernie Sanders asked recently, if the government paid for companies' research, enough to ensure they make a reasonable profit? By Matthew Herper STAT+ | Wary of changes to Medicare Advantage, health insurers put up a fight — and exaggerate the stakes Insurers are distorting the reality of the proposals in a bid to protect the sizable and growing profits they earn from Medicare Advantage. By Bob Herman

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Cancer Briefing? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser